Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Blood (2023) 142 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2023-187020

Published: 2023

Journal Articles

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Patrick K Reville, John Davis, Christine Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Sanam Loghavi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2023-190655

Published: 2023

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva

Blood (2022) 140 (Supplement 1): 1293–1294.

https://doi.org/10.1182/blood-2022-170956

Published: 2022

Journal Articles

Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Siba El Hussein, Pingjun Chen, Morteza Salehjahromi, Hong Fang, Wei Wang, Sanam Loghavi, Patrick M. Reagan, Jonathan W. Friedberg, Richard Burack, Andrew G Evans, L. Jeffrey Medeiros, Jia Wu, Joseph D. Khoury

Blood (2022) 140 (Supplement 1): 7836–7837.

https://doi.org/10.1182/blood-2022-166610

Published: 2022

Journal Articles

Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification

Wolfgang Kern, Prashant R. Tembhare, Reza Nejati, Fatima Zahra Jelloul, Wencke Walter, Joseph D. Khoury, Torsten Haferlach

Blood (2022) 140 (Supplement 1): 8908–8909.

https://doi.org/10.1182/blood-2022-165918

Published: 2022

Journal Articles

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Blood (2022) 140 (Supplement 1): 6306–6308.

https://doi.org/10.1182/blood-2022-164494

Published: 2022

Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Blood (2022) 140 (Supplement 1): 11698–11701.

https://doi.org/10.1182/blood-2022-170049

Published: 2022

Journal Articles

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

Rasoul Pourebrahim, Rafael Heinz Montoya, Edward Ayoub, Hiroki Akiyama, Natalia Baran, Tom Lesluyes, Lauren B Ostermann, Bin Liu, Jo Ishizawa, Joseph D. Khoury, Marina Konopleva, Peter Van Loo, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5876–5878.

https://doi.org/10.1182/blood-2022-167859

Published: 2022

Journal Articles

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Mehrnoosh Tashakori, Tapan Kadia, Sanam Loghavi, Naval Daver, Rashmi Kanagal-Shamanna, Sherry Pierce, Dawen Sui, Peng Wei, Farnoosh Khodakarami, Zhenya Tang, Mark Routbort, Carol A. Bivins, Elias J. Jabbour, L. Jeffrey Medeiros, Kapil Bhalla, Hagop M. Kantarjian, Farhad Ravandi, Joseph D. Khoury

Blood (2022) 140 (1): 58–72.

https://doi.org/10.1182/blood.2021013983

Published: 2022

Includes: Supplemental data

Journal Articles

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Christopher P. Mill, Warren Fiskus, Courtney D. DiNardo, Christine Birdwell, John A. Davis, Tapan M. Kadia, Koichi Takahashi, Nicholas Short, Naval Daver, Maro Ohanian, Gautam Borthakur, Steven M. Kornblau, Michael R. Green, Yuan Qi, Xiaoping Su, Joseph D. Khoury, Kapil N. Bhalla

Blood (2022) 139 (6): 907–921.

https://doi.org/10.1182/blood.2021013156

Published: 2022

Includes: Supplemental data

Journal Articles

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 1233.

https://doi.org/10.1182/blood-2021-154022

Published: 2021

Journal Articles

Mdm2 Maintains Cholesterol Biosynthesis in Hematopoietic Stem/Progenitor Cells Independent of p53

Rasoul Pourebrahim, Rafael Heinz Montoya, Edward Ayoub, Joseph D. Khoury, Michael Andreeff

Blood (2021) 138 (Supplement 1): 1152.

https://doi.org/10.1182/blood-2021-152899

Published: 2021

Journal Articles

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2021-154074

Published: 2021

Journal Articles

Molecular Characterization Using Oncoscan Chromosome Microarray in an International Cohort of 51 Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Eli Williams, Stefano A Pileri, Maria Rosaria Sapienza, Carlos Barrionuevo, Carlos Bacchi, Maxime Battistella, Tony Petrella, Emmanuella Guenova, Daniela Dueñas, Sandro Casavilca, Joseph D. Khoury, Jose Plaza, Pierluigi Porcu, Alejandro Ariel Gru

Blood (2021) 138 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2021-152922

Published: 2021

Journal Articles

Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy

Naveen Pemmaraju, Nathaniel R Wilson, Guillermo Garcia-Manero, Koji Sasaki, Joseph D. Khoury, Nitin Jain, Gautam Borthakur, Farhad Ravandi, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Elias J. Jabbour, Sherry A. Pierce, John Villarreal, Muzaffar H. Qazilbash, Marina Konopleva, Hagop Kantarjian

Blood (2021) 138 (Supplement 1): 2319.

https://doi.org/10.1182/blood-2021-154205

Published: 2021

Journal Articles

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2021) 138 (Supplement 1): 2626.

https://doi.org/10.1182/blood-2021-154195

Published: 2021

Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Blood (2021) 138 (Supplement 1): 3363.

https://doi.org/10.1182/blood-2021-154155

Published: 2021

Journal Articles

Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Blood (2021) 138 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2021-154351

Published: 2021

Journal Articles

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Curtis Lachowiez, Courtney D. DiNardo, Kiyomi Morita, Ken Furudate, Feng Wang, Tomoyuki Tanaka, Sa A Wang, Tapan M. Kadia, Naval Daver, Nicholas J. Short, Joseph D. Khoury, Keyur Patel, L. Jeffrey Medeiros, Marina Konopleva, Farhad Ravandi, Koichi Takahashi, Sanam Loghavi

Blood (2021) 138 (Supplement 1): 607.

https://doi.org/10.1182/blood-2021-148971

Published: 2021

Journal Articles

Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases

Pingjun Chen, Siba Elhussein, L. Jeffrey Medeiros, Joseph D. Khoury, Jia Wu

Blood (2021) 138 (Supplement 1): 3738.

https://doi.org/10.1182/blood-2021-149540

Published: 2021

NARROW

Does Detection of <20% Lymphoblasts in Patients with CML Herald Imminent Blast Crisis? a Study from BCR::ABL1 Pathology Group

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2

Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Mdm2 Maintains Cholesterol Biosynthesis in Hematopoietic Stem/Progenitor Cells Independent of p53

Updated Results from a Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Molecular Characterization Using Oncoscan Chromosome Microarray in an International Cohort of 51 Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy

Venetoclax, Obinutuzumab and Atezolizumab (PD-L1 Checkpoint Inhibitor) for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Longitudinal Next Generation Sequencing Reveals the Clonal Hierarchy of IDH Mutated Clones and Impact on Survival in NPM1 Mutated AML

Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only